99mTc Tamoxifen for Imaging Estrogen Receptor Expression in Metastatic Breast Cancer Patient.
Journal
Clinical nuclear medicine
ISSN: 1536-0229
Titre abrégé: Clin Nucl Med
Pays: United States
ID NLM: 7611109
Informations de publication
Date de publication:
Mar 2020
Mar 2020
Historique:
pubmed:
25
1
2020
medline:
29
5
2020
entrez:
25
1
2020
Statut:
ppublish
Résumé
Estrogen receptor-expressing breast cancer exhibits better prognosis due to responsiveness to antiestrogen treatment. Therefore, knowledge of the estrogen receptor status of a tumor is an important prognostic and predictive indicator in breast cancer. We present noninvasive imaging of estrogen receptors with Tc tamoxifen that can identify the active tumor and approachable sites for biopsy. It may help in selection of patients for hormone replacement therapy and in assessment of receptor status in recurrent disease and also in response evaluation.
Identifiants
pubmed: 31977463
doi: 10.1097/RLU.0000000000002900
pii: 00003072-202003000-00015
doi:
Substances chimiques
Radiopharmaceuticals
0
Receptors, Estrogen
0
Tamoxifen
094ZI81Y45
Technetium
7440-26-8
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
225-227Commentaires et corrections
Type : ErratumIn
Références
Leong A, Zhuang Z. The changing role of pathology in breast cancer diagnosis and treatment. Pathobiology. 2011;78:99–114.
Vaalavirta L, Rasulova N, Partanen K, et al. F-18-estradiol PET/CT imaging in breast cancer patients. J Diagn Imaging Ther. 2014;1:59–72.
Liao GJ, Clark AS, Schubert EK, et al. F-18-fluoroestradiol PET: current status and potential future clinical applications. J Nucl Med. 2016;57:1269–1275.
Gong C, Yang Z, Sun Y, et al. A preliminary study of F-18 FES PET/CT in predicting metastatic breast cancer in patients receiving docetaxel or fulvestrant with docetaxel. Sci Rep. 2017;7:6584.
Muftuler FZ, Unak P, Teksoz S, et al. 131I labeling of tamoxifen and biodistribution studies in rats. Appl Radiat Isot. 2008;66:178–187.
Wallace S, Yang D, Delpassand E, et al. High Affinity Tamoxifen Derivatives. US6096874A. Alexandria, VA: United States Patent and Trademark Office; 2000.
Gallo MA, Kaufman D. Antagonistic and agonistic effects of tamoxifen: significance in human cancer. Semin Oncol. 1997;24(suppl 1):71–80.
Vorobiof DA. Recent advances in the medical treatment of breast cancer. F1000Res. 2016;5:2786.